Industry Veterans to Join as Chief Medical Officer and Chief Financial Officer
BOSTON, Mass., December 8, 2020 – Entrada Therapeutics, a privately-held biotechnology
company dedicated to transforming the treatment of devastating diseases using intracellular
biologics, today announced the appointments of Nerissa Kreher, M.D., as Chief
Medical Officer and Kory Wentworth as Chief Financial Officer.
Dr. Kreher, a physician executive with a 15-year record of
driving growth at start-ups and larger biotech/pharma companies, comes to
Entrada after building clinical and regulatory strategy as Chief Medical
Officer at both AVROBIO and Tiburio Therapeutics. Previously, Dr. Kreher was Global Head of
Clinical and Medical Affairs at Zafgen, and has held positions of increasing
responsibility at EMD Serono, Genzyme, Enobia/Alexion and Shire
Pharmaceuticals. She is a board-certified pediatric endocrinologist and began
her career as Chief Resident and then attending physician at the Riley Hospital
for Children in Indianapolis, Indiana.
“I’ve spent my career helping companies bring new therapies
to underserved patient populations,” said Dr. Kreher. “I’m thrilled to join the
Entrada team, and to help the company advance a growing and promising pipeline
of programs targeting diseases where no adequate treatments for patients exist.”
Mr. Wentworth joins Entrada with 19 years of public
accounting and global biopharmaceutical experience. Most recently serving as Vice
President, Finance and Treasurer, Principal Accounting Officer at bluebird bio,
Mr. Wentworth built a global finance team to support operational expansion,
commercial product launches, equity financing and strategic collaboration
arrangements. Prior to joining bluebird bio, Mr. Wentworth served as Executive
Director and Corporate Controller for Alexion Pharmaceuticals and has held
positions of increasing responsibility at PricewaterhouseCoopers LLP, KPMG and
Arthur Andersen.
“Entrada is leading the field of intracellular biologics and
developing an exciting portfolio,” said Mr. Wentworth. “I look forward to working
with the team to shape the Company’s capital formation strategy and build the finance
function.”
"We are delighted to have two extraordinarily high
caliber executives stepping into leadership roles at Entrada,” said Dipal
Doshi, President and Chief Executive Officer. “Nerissa is ideally suited to
serve as our Chief Medical Officer given her experience across a wide range of
therapeutic areas and Kory brings a proven ability to lead the development of
the finance organization. Both Nerissa and Kory are joining Entrada at an
exciting point in our Company’s growth trajectory and we look forward to having
their leadership on our executive team.”
About Entrada Therapeutics
Entrada Therapeutics’ mission is to treat devastating
diseases by developing intracellular biologics. Using its proprietary EEV™ platform,
Entrada is creating a diverse pipeline of oligonucleotide, enzyme, protein and
peptide programs to efficiently engage intracellular disease targets across
multiple therapeutic areas. The Company’s novel approach addresses current
challenges associated with both large and small molecule therapeutics and represents
a fundamental advancement in the field of intracellular biologics. Entrada is backed by 5AM Ventures, MPM Capital,
Roche Venture Fund, MRL Ventures Fund and Agent Capital. For more information,
please visit www.entradatx.com.
###
Company Contact:
Nathan Dowden
Entrada Therapeutics, Inc.
ndowden@entradatx.com
Investor Contact:
Felicia Vonella
W2O Group
fvonella@w2ogroup.com
Media Contact:
Aulani Capuchin
W2O Group
(559) 355-2673
acapuchin@w2ogroup.com
